Paper · 39764422
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
Testi I and 7 others. Explor Target Antitumor Ther, 2024. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives. Papers, record 39764422. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39764422
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References139
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,315,352 | INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. | PLoS One | 2020 | https://conductscience.org/library/papers/32315352 | PubMed |
| 2 | 21,551,320 | Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. | J Histochem Cytochem | 2011 | https://conductscience.org/library/papers/21551320 | PubMed |
| 3 | 34,782,263 | Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. | Clin Genitourin Cancer | 2022 | https://conductscience.org/library/papers/34782263 | PubMed |
| 4 | 28,911,922 | Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. | Urol Oncol | 2018 | https://conductscience.org/library/papers/28911922 | PubMed |
| 5 | 38,754,471 | NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. | J Natl Compr Canc Netw | 2024 | https://conductscience.org/library/papers/38754471 | PubMed |
| 6 | 24,821,883 | Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/24821883 | PubMed |
| 7 | 25,459,391 | Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. | Eur J Cancer | 2015 | https://conductscience.org/library/papers/25459391 | PubMed |
| 8 | 32,861,617 | Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. | Eur Urol Focus | 2021 | https://conductscience.org/library/papers/32861617 | PubMed |
| 9 | 36,216,658 | Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. | Eur Urol | 2023 | https://conductscience.org/library/papers/36216658 | PubMed |
| 10 | 25,384,433 | Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. | Int Urol Nephrol | 2015 | https://conductscience.org/library/papers/25384433 | PubMed |
1 to 10 of 139
See all 139 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,500,580 | Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder. | Oncol Res | 2026 | https://conductscience.org/library/papers/42500580 | PubMed |
| 42,164,551 | Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery. | Eur Urol Open Sci | 2026 | https://conductscience.org/library/papers/42164551 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2,064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NECTIN4 | 81,607 | PubTator's text mining | https://conductscience.org/library/genes/81607 | NCBI Gene |
| TACSTD2 | 4,070 | PubTator's text mining | https://conductscience.org/library/genes/4070 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39764422
GET https://conductscience.org/api/papers/v1/39764422/references?page=2